Suppr超能文献

使用明胶/淀粉/FeO 纳米载体靶向递送槲皮素以抑制肝癌 HepG2 细胞的生长。

Targeted delivery of quercetin using gelatin/starch/FeO nanocarrier to suppress the growth of liver cancer HepG2 cells.

机构信息

Department of Applied Chemistry, Faculty of Science, South Tehran Branch, Islamic Azad University, Tehran, Iran.

Department of Chemistry, Amirkabir University of Technology, Tehran, P.O. Box 15875-4413, Tehran, Iran.

出版信息

Int J Biol Macromol. 2024 Nov;281(Pt 4):136535. doi: 10.1016/j.ijbiomac.2024.136535. Epub 2024 Oct 12.

Abstract

To suppress HepG2 liver cancer cells, a nanocarrier (NC) consisting of FeO, Gelatin (G), and Starch (S) was synthesized and characterized for targeted delivery of Quercetin (QC) drug. The spectra obtained from X-ray diffraction (XRD) and Fourier transform infrared (FTIR) demonstrated that the nanoparticles (NP) in the NC are well-interconnected to each other and have formed a regular structure. Also, field emission scanning electron microscopy (FE-SEM) indicates a smooth and homogeneous surface of the synthesized NC. The results of the vibrating sample magnetometer (VSM) also corroborated the correctness of the synthesis of FeO NPs and Gelatin/Starch/FeO@Quercetin NC (G/S/FeO@QC) because the magnetic properties of FeO decreased with the addition of G/S@QC. Stability and particle size were determined by zeta potential and Dynamic light scattering (DLS). The percentage of drug loading and encapsulation efficiency of QC in the NC was 46.25 % and 87 %, respectively. QC profile release in acidic and natural environments showed controlled release and pH sensitivity of the NC. Cytotoxicity of L929 and HepG2 treated cells with the G/S/FeO@QC was investigated by MTT staining, which agreed with the flow cytometry result. The results of Flowcytometry and MTT showed 43.5 % apoptosis and 42 % cytotoxicity in treated HepG2 cells by G/S/FeO@QC, while it was not toxic to L929 normal cells. According to the results, G/S/FeO@QC is a suitable NC for the targeted delivery of QC as a drug against HepG2 cancer cells.

摘要

为了抑制 HepG2 肝癌细胞,我们合成了一种由 FeO、明胶(G)和淀粉(S)组成的纳米载体(NC),用于槲皮素(QC)药物的靶向递送。X 射线衍射(XRD)和傅里叶变换红外(FTIR)光谱表明,NC 中的纳米颗粒(NP)相互之间连接良好,并形成了规则的结构。此外,场发射扫描电子显微镜(FE-SEM)表明合成的 NC 具有光滑均匀的表面。振动样品磁强计(VSM)的结果也证实了 FeO NPs 和 Gelatin/Starch/FeO@Quercetin NC(G/S/FeO@QC)的合成是正确的,因为 FeO 的磁性随着 G/S@QC 的加入而降低。通过zeta 电位和动态光散射(DLS)测定了稳定性和粒径。NC 中 QC 的载药量和包封效率分别为 46.25%和 87%。NC 在酸性和自然环境中的 QC 释放曲线显示了 NC 的控制释放和 pH 敏感性。通过 MTT 染色法研究了 L929 和 HepG2 细胞用 G/S/FeO@QC 处理后的细胞毒性,结果与流式细胞术结果一致。流式细胞术和 MTT 的结果表明,G/S/FeO@QC 处理 HepG2 细胞后,细胞凋亡率为 43.5%,细胞毒性为 42%,而对 L929 正常细胞没有毒性。根据这些结果,G/S/FeO@QC 是一种适合用于靶向递送 QC 的 NC,可作为治疗 HepG2 癌细胞的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验